{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:20:59Z","timestamp":1784092859754,"version":"3.55.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Rituximab (RTX) is a chimeric human\/murine CD20 monoclonal antibody, which has been administered in treating hematological malignancies and various autoimmune disorders. This study aimed to present our center\u2019s experience in RTX use in adults with lymphoma and autoimmune diseases (AID) including primary membranous nephropathy (pMN), as well as therapeutic effects of RTX on clinical outcome of pMN patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 761 Chinese patients were retrospectively included, who received RTX treatment at Shandong Provincial Hospital between January 1st, 2017 and December 31st, 2021, with person time of exposure spanning between their first dose of RTX and last follow-up date or the end of the study period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Adverse events (AEs) occurred in 487 patients (64.0%), with a majority of infection (309, 40.6%) and a minority of non-infectious AEs (178, 23.4%); and the incidences of AEs were higher in lymphoma patients (381, 65.8%) than that in AID patients (106, 58.2%). Respiratory infections (215, 28.3%), gastrointestinal infections (49, 6.4%), urinary tract infections (41, 5.4%), cutaneous and mucosal infections (31, 4.1%), and infections in the abdominal cavity or pleurisy (4, 0.5%) were the leading types of infections. Cancer diagnosis [hazard ratio (HR), 3.926; 95% confidence interval (CI), 1.730\u20138.913] and prophylactic sulfamethoxazole\/trimethoprim (SMZ\/TMP) administration (HR, 3.793; 95% CI, 1.101\u201313.069) were associated with increased risk of infections. Immediate non-infectious AEs included anaphylaxis (44, 5.8%) and infusion reactions (99, 13.0%). Long-term non-infectious AEs included hypogammaglobulinemia (106, 28.6%), neutropenia (11, 5.5%) and interstitial lung disease (1, 0.1%). Female sex (HR, 0.515; 95% CI, 0.289\u20130.918) and cancer diagnosis (HR, 0.126; 95% CI, 0.049-0.323) were associated with higher risk of hypogammaglobulinemia. In 74 pMN patients, 13 (17.6%) patients experienced infections, with 2 cases of non-infectious AEs (2.7%). 6-month follow-up showed remission was achieved in 45 patients (60.8%), either as initial (61.0%) or alternative therapy (60.7%), without significant impacts on kidney function (<jats:italic>p<\/jats:italic>\u202f&amp;gt;\u202f0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings indicated AEs were common during RTX treatment, particularly in lymphoma patients, most of which were moderate and mild, highlighting a whole-process monitoring, timely interference and caring. And RTX was a safe and effective therapeutic option for pMN either as initial or alternative therapy in adult Chinese patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1567886","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:23:19Z","timestamp":1745558599000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of rituximab use with adverse events in adults with lymphoma or autoimmune disease: a single center experience"],"prefix":"10.3389","volume":"12","author":[{"given":"Mengsi","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: a systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/10428190902934944","article-title":"The late adverse events of rituximab therapy--rare but there!","volume":"50","author":"Ram","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/sonc.2003.50025","article-title":"The mechanisms of action of rituximab in the elimination of tumor cells","volume":"30","author":"Johnson","year":"2003","journal-title":"Semin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-Cd20 monoclonal antibody (Idec-C2b8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jpeds.2012.11.038","article-title":"Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States","volume":"162","author":"Kavcic","year":"2013","journal-title":"J Pediatr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1146\/annurev.med.55.091902.104249","article-title":"Rituximab: expanding role in therapy for lymphomas and autoimmune diseases","volume":"55","author":"Rastetter","year":"2004","journal-title":"Annu Rev Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1517\/14712598.2012.646984","article-title":"Update on the role of rituximab in kidney diseases and transplant","volume":"12","author":"Ramanath","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"213-9 e2","DOI":"10.1016\/j.jpeds.2017.05.002","article-title":"Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: a systematic review","volume":"187","author":"Mahmoud","year":"2017","journal-title":"J Pediatr"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bcp.13548","article-title":"Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome","volume":"84","author":"Bonanni","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/infdis\/jiaa256","article-title":"High risk of clinical relapse in patients with chronic hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy","volume":"222","author":"Chang","year":"2020","journal-title":"J Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1177\/1078155219879496","article-title":"Development of pneumonitis after rituximab treatment in a patient with lymphoma","volume":"26","author":"Mert","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J Neurovirol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"CS133","DOI":"10.12659\/msm.882034","article-title":"Rituximab associated neutropenia: description of three cases and an insight into the underlying pathogenesis","volume":"17","author":"Weissmann-Brenner","year":"2011","journal-title":"Med Sci Monit"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"859419","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/MNH.0000000000000697","article-title":"Membranous nephropathy: current understanding of various causes in light of new target antigens","volume":"30","author":"Ronco","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7a in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New 'antigens' in membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000358887","article-title":"Update on rituximab: an established treatment for all immune-mediated kidney diseases?","volume":"126","author":"Evans","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2215\/CJN.06041108","article-title":"Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients","volume":"4","author":"Segarra","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref29","first-page":"S1","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney diseases","volume-title":"Kidney Int.","year":"2020"},{"key":"ref30","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) (Version 5.0)","year":"2017"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/all.15032","article-title":"Eaaci guidelines: anaphylaxis (2021 update)","volume":"77","author":"Muraro","year":"2022","journal-title":"Allergy"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2215\/CJN.10611110","article-title":"Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab","volume":"6","author":"Guiard","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e23455","DOI":"10.1002\/jcla.23455","article-title":"Infection risk in autoimmune hematological disorders with low-dose rituximab treatment","volume":"34","author":"Wang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"663680","DOI":"10.3389\/fmed.2021.663680","article-title":"Rituximab therapy for primary membranous nephropathy in a Chinese cohort","volume":"8","author":"Gao","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1517\/14740338.2011.562188","article-title":"The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis","volume":"10","author":"Brinkman","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000509893","article-title":"Severe infections following rituximab treatment in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Li","year":"2021","journal-title":"Kidney Dis (Basel)"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e2036321","DOI":"10.1001\/jamanetworkopen.2020.36321","article-title":"Association of rituximab use with adverse events in children, adolescents, and young adults","volume":"4","author":"McAtee","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1741-7015-9-36","article-title":"Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis","volume":"9","author":"Lanini","year":"2011","journal-title":"BMC Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.4049\/jimmunol.1004095","article-title":"Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens","volume":"186","author":"Bedognetti","year":"2011","journal-title":"J Immunol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.chest.2021.11.007","article-title":"Primary prophylaxis for pneumocystis Jirovecii pneumonia in patients receiving rituximab","volume":"161","author":"Park","year":"2022","journal-title":"Chest"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"882891","DOI":"10.3389\/fmed.2022.882891","article-title":"Differences in the development of adverse infusion reactions to rituximab in patients with systemic lupus erythematosus, rheumatoid arthritis and non-Hodgkin's lymphoma-enigma variations","volume":"9","author":"Gilaberte Reyzabal","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1080\/10428194.2017.1306648","article-title":"Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients","volume":"58","author":"D'Arena","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1186\/ar1008","article-title":"Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis","author":"Hainsworth","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaip.2016.06.022","article-title":"Reactions to rituximab in an outpatient infusion center: a 5-year review","volume":"5","author":"Levin","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","article-title":"Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment","volume":"124","author":"Brennan","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3389\/fimmu.2019.01653","article-title":"Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome","volume":"10","author":"Colucci","year":"2019","journal-title":"Front Immunol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10875-024-01773-y","article-title":"Hypogammaglobulinemia and infection events in patients with autoimmune diseases treated with rituximab: 10 years real-life experience","volume":"44","author":"Nie","year":"2024","journal-title":"J Clin Immunol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00467-019-04398-1","article-title":"Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome","volume":"35","author":"Parmentier","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/10428194.2021.2010058","article-title":"The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma","volume":"63","author":"Fischer","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/10428194.2020.1832673","article-title":"The prognostic roles of hypogammaglobulinemia and hypocomplementemia in newly diagnosed diffuse large B-cell lymphoma","volume":"62","author":"Pan","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-021-05345-9","article-title":"Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome","volume":"37","author":"Chan","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"671503","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front Immunol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/rheumatology\/kex484","article-title":"Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis","volume":"57","author":"Cornec","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/ndt\/gfm683","article-title":"Rituximab and nephrotic syndrome: a new therapeutic hope?","volume":"23","author":"Ahmed","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"738788","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab immunomonitoring predicts remission in membranous nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front Immunol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2215\/CJN.01080905","article-title":"Rituximab for idiopathic membranous nephropathy: who can benefit?","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Boyer-Suavet","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","article-title":"Detection and quantification of rituximab in the human urine","volume":"451","author":"Jacobs","year":"2017","journal-title":"J Immunol Methods"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","article-title":"Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics","volume":"5","author":"Golay","year":"2013","journal-title":"MAbs"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ejphar.2024.176928","article-title":"Novel approaches to primary membranous nephropathy: beyond the KDIGO guidelines","volume":"982","author":"Yang","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2020","journal-title":"Front Immunol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1002\/cpz1.897","article-title":"Measurement of trogocytosis: quantitative analyses validated with rigorous controls","volume":"3","author":"Taylor","year":"2023","journal-title":"Curr Protocols"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/art.39167","article-title":"Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus","volume":"67","author":"Reddy","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1182\/blood-2014-07-585976","article-title":"Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centers","volume":"124","author":"Wallin","year":"2014","journal-title":"Blood"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-025-02249-w","article-title":"Exploring the role of Traf 6-Tak 1 pathway in podocyte pyroptosis and its implications for primary membranous nephropathy therapy","author":"Guo","year":"2025","journal-title":"Inflammation"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41401-023-01148-w","article-title":"Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt 1\/\u0392-catenin pathway","volume":"45","author":"Miao","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"154763","DOI":"10.1016\/j.phymed.2023.154763","article-title":"Moshen granule ameliorates membranous nephropathy by blocking Intrarenal renin-angiotensin system signalling via the Wnt 1\/\u0392-catenin pathway","volume":"114","author":"Wang","year":"2023","journal-title":"Phytomedicine"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"116583","DOI":"10.1016\/j.biopha.2024.116583","article-title":"Activation of the IL-6\/STAT 3 pathway contributes to the pathogenesis of membranous nephropathy and is a target for Mahuang Fuzi and Shenzhuo decoction (MFSD) to repair podocyte damage","volume":"174","author":"Zhao","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bph.16219","article-title":"Lactobacillus species ameliorate membranous nephropathy through inhibiting the aryl hydrocarbon receptor pathway via tryptophan-produced indole metabolites","volume":"181","author":"Miao","year":"2023","journal-title":"Br J Pharmacol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fmicb.2021.645500","article-title":"Lactobacillus Reuteri alleviates gastrointestinal toxicity of rituximab by regulating the proinflammatory T cells in vivo","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Microbiol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1567886\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:23:20Z","timestamp":1745558600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1567886\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":80,"alternative-id":["10.3389\/fmed.2025.1567886"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1567886","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"1567886"}}